What does Diakonos Oncology do?

Diakonos Oncology Corp. is a clinical-stage biotechnology company based in Houston, Texas, founded in 2006. The company specializes in dendritic cell immunotherapies aimed at treating late-stage and aggressive cancers, including glioblastoma multiforme (GBM) and pancreatic ductal adenocarcinoma (PDAC). Diakonos develops personalized autologous dendritic cell vaccines, particularly DOC1021 (dubodencel), which utilizes a unique "double-loading" technique to enhance immune response without the need for extensive modifications. The company originated from research at Baylor College of Medicine and collaborates with notable institutions such as MD Anderson and UTHealth Houston. Diakonos has raised significant funding to support its clinical trials, including a recent $20 million private placement aimed at advancing its Phase 2 GBM trial. The company has received FDA Fast Track designations for both GBM and pancreatic cancer, along with Orphan Drug Designation for GBM. Access to DOC1021 is available through clinical trials and expanded access inquiries.